Previous 10 | Next 10 |
Facing record-high volatility and market uncertainty, one biotech is scheduled for the week ahead. Formed by New Enterprise Associate's orphan drug accelerator Cydan, genetic disorder biotech Imara (IMRA) plans to raise $76 million at a $301 million market cap. The Boston-based company's sol...
PLEASANTON, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 40th Annual Cowen Health Care Conference in Boston, MA. 10x Genomics’ management is scheduled to present on Tuesday, March 3 at...
PLEASANTON, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- 10x Genomics , Inc. (Nasdaq: TXG) today announced a broad range of new products at the Advances in Genome Biology and Technology (AGBT) General Meeting, as well as new capabilities for existing products. Today’s announcements f...
Image source: The Motley Fool. 10x Genomics Inc (NASDAQ: TXG) Q4 2019 Earnings Call Feb 18, 2020 , 4:30 p.m. ET Operator Continue reading
10x Genomics, Inc. (TXG) Q4 2019 Earnings Conference Call February 18, 2020 4:30 PM ET Company Participants Serge Saxonov - Co-Founder & Chief Executive Officer Justin McAnear - Chief Financial Officer Brad Crutchfield - Chief Commercial Officer Conference Call Participant...
Gainers: QUAD +21.6% . ENPH +10.4% . MITO +5.7% . HLF +5.1% . SCPL +4.7% . More news on: Quad/Graphics, Inc., Enphase Energy, Inc., Stealth BioTherapeutics Corp, Stocks on the move, , , News on ETFs Read more ...
10x Genomics (NASDAQ: TXG ) Q4 results : More news on: 10x Genomics, Inc., Healthcare stocks news, Stocks on the move, Earnings news and commentary, , Read more ...
10x Genomics (NASDAQ: TXG ): Q4 GAAP EPS of -$0.07 beats by $0.04 . More news on: 10x Genomics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
PLEASANTON, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the fourth quarter and full year ended December 31, 2019. Recent Highlights Revenue of $75.3 million for the fourth quarter and $245.9 million for the full ye...
PLEASANTON, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2019 after market close on Tuesday, February 18, 2020. Company management will host a corresponding confe...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...